tradingkey.logo

tradingkey.logo
怜玢


Parabilis Medicines Ord Shs

PBLS
りォッチリストに远加
28.430USD
+0.740+2.67%
終倀 11-13 16:00ET
3.47B時䟡総額
0.00盎近12ヶ月PER

Parabilis Medicines Ord Shsに぀いお 䌁業名

Parabilis Medicines, Inc., formerly FOG Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. It is built to develop transformative medicines addressing undruggable protein targets driving human disease. It leverages a proprietary platform to a novel therapeutic modality, Helicons, which are stabilized helical peptides engineered to bind and precisely modulate proteins that reach conventional medicine. Its lead product candidate, zolucatetide, is the first and only investigational therapy that inhibits the b-catenin: TCF interaction, the critical downstream node of the Wnt/b-catenin pathway. Its preclinical pipeline provides Helicon approach and includes programs targeting two key drivers of prostate cancer, the ETS-related gene and the androgen receptor (AR) in its active state (ARON). Helicon discovery platform integrates advanced AI and physics-based computational modeling with peptide synthesis and experimental screening to discover and develop drug candidates.

Parabilis Medicines Ord Shs プロフィヌル


䌁業コヌド- -
䌚瀟名- -
䞊堎日- -
最高経営責任者「CEO」- -
埓業員数- -
蚌刞皮類- -
決算期末- -
本瀟所圚地- -
郜垂- -
蚌刞取匕所- -
囜- -
郵䟿番号- -
電話番号- -
りェブサむト- -
䌁業コヌド- -
䞊堎日- -
最高経営責任者「CEO」- -

Parabilis Medicines Ord Shsの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Fawzi Benzaghou, M.D.
Dr. Fawzi Benzaghou, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Helen Ho, Ph.D.
Dr. Helen Ho, Ph.D.
Chief Business and Strategy Officer
Chief Business and Strategy Officer
--
--
Mr. Thomas (Tom) Kotarakos
Mr. Thomas (Tom) Kotarakos
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Rohin Mhatre, Ph.D.
Mr. Rohin Mhatre, Ph.D.
Chief Technical Operations Officer
Chief Technical Operations Officer
--
--
Ms. Teresa Jurgensen, J.D.
Ms. Teresa Jurgensen, J.D.
General Counsel
General Counsel
--
--
Mr. Alexis Borisy
Mr. Alexis Borisy
Lead Independent Director
Lead Independent Director
--
--
Mr. Edward M. Fitzgerald
Mr. Edward M. Fitzgerald
Independent Director
Independent Director
--
--
Dr. Mathai Mammen, M.D., Ph.D.
Dr. Mathai Mammen, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Dr. Rick Klausner, M.D.
Dr. Rick Klausner, M.D.
Independent Director
Independent Director
--
--
Mr. Alan M. Sebulsky
Mr. Alan M. Sebulsky
Independent Director
Independent Director
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Fawzi Benzaghou, M.D.
Dr. Fawzi Benzaghou, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Helen Ho, Ph.D.
Dr. Helen Ho, Ph.D.
Chief Business and Strategy Officer
Chief Business and Strategy Officer
--
--
Mr. Thomas (Tom) Kotarakos
Mr. Thomas (Tom) Kotarakos
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Rohin Mhatre, Ph.D.
Mr. Rohin Mhatre, Ph.D.
Chief Technical Operations Officer
Chief Technical Operations Officer
--
--
Ms. Teresa Jurgensen, J.D.
Ms. Teresa Jurgensen, J.D.
General Counsel
General Counsel
--
--
Mr. Alexis Borisy
Mr. Alexis Borisy
Lead Independent Director
Lead Independent Director
--
--

よくある質問

Parabilis Medicines Ord Shsの䞊䜍5名の株䞻は誰ですか


Parabilis Medicines Ord Shsの䞊䜍5名の株䞻は以䞋のずおりです。Dr. Fawzi Benzaghou, M.D.
tradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。